Site Search

1. 11.
   AMP/assets/File/advocacy/Survey_Report_August_2020_AMP_SARSCoV2_FINAL.pdf?pass=5

   That survey is available here: https://www.amp.org/advocacy/sars- ... SARS-CoV-2 diagnostic testing, 72% (76) performing screening testing, and 29% (30) performing surveillance testing. Samples originating ... government-procured supplies, only about 40% felt that these supplies aided their ... August, that number increased to 54%. Respondents indicated in April that they

   https://www.amp.org/AMP/assets/File/advocacy/Survey_Report_August_2020_AMP_SARSC...
2. 12.
   AMP/assets/File/education/MIMP/Hematopathology.pdf?pass=20

   Common secondary karyotypic abnormalities include -7 (50% cases), del(5q) ... AML-MR) • >20% blasts required by WHO ... NUP) • KMT2A rearrangement (~8%) • NUP214::ABL1 ( 6% cases) • MYC rearrangements (~6% cases) • NOTCH1 (70% cases), CDKN2A/B (cryptic deletions >70% cases) mutations Early T ... DUSP22 and IRF4; ~30%) -good prognosis • TP63 rearrangement

   https://www.amp.org/AMP/assets/File/education/MIMP/Hematopathology.pdf?pass=20
3. 13.
   PowerPoint Presentation

   Lynch and constitutional mismatch repair deficiency•MGMT promoter methylation (40-50%) predicts better outcomes with ... mutation in H3F3A (H3-3A)-p.G35R, p.G35V ... of SMARCB1 or SMARCA4 ( 5%)•3 subtypes by methylation profiling ... sub grouped•WNT-activated (10%)•CTNNB1, DDX3X mutation; monosomy 6 ... FLI1 accounts for 85% cases (t11:22)(q24

   https://www.amp.org/AMP/assets/File/education/MIMP/Neuropathology.pdf?pass=22
4. 14.
   AMP/assets/File/education/MIMP/PGXTesting_Reccomendation1.pdf?pass=49

   No function rs9332131 c.818delA 0-1% CYP2C9*8 Decreased function rs7900194 ... function rs35742686 c.775del 0.1-1.6% CYP2D6*4 No function rs3892097 c ... function rs5030655 c.454del 0-1.1% CYP2D6*9 Decreased function rs5030656 c ... of function can be found at https://www.pharmvar.org (last accessed 9 ... rs774671100 c.137dup 0-0.6% CYP2D6*21 No function rs72549352,

   https://www.amp.org/AMP/assets/File/education/MIMP/PGXTesting_Reccomendation1.pd...
5. 15.
   AMP/assets/File/advocacy/AMP_Testimony_Senate_Hearing_PERA.pdf?pass=90

   B699-41AC-BE62-9DCA9460EDDA 3 https://www.genomeweb.com/molecular-diagnostics/ ... license. Moreover, fifty-three percent (53%) of respondents decided not to develop ... on patient access to genetic tests. https://osp.od.nih.gov/wp-content ... Utah, filed July 9, 2013) 7 https://www.nytimes.com/2013/06/14 ... 29 As one example, see https://www.wired.com/story/one-

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Testimony_Senate_Hearing_PERA.p...
6. 16.
   AMP/assets/File/advocacy/AMP_Testimony_Senate_Hearing_Patent_EligibilityFINAL.pdf?...

   Text of PERA 1 https://www.amp.org/AMP/assets/ ... 04D9DCF2-B699-41AC-BE62-9DCA9460EDDA 3 https://www.genomeweb.com/molecular-diagnostics/decade ... license. Moreover, fifty-three percent (53%) of respondents decided not to develop ... on patient access to genetic tests. https://osp.od.nih.gov/wp-content ... Utah, filed July 9, 2013) 7 https://www.nytimes.com/2013/06/14

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Testimony_Senate_Hearing_Patent...
7. 17.
   AMP/assets/File/advocacy/AMP_LDT_Proposed_Rule_Comments_FINAL_12_2_23.pdf?pass=49

   Table 42 of the impact analysis. 8 https://www.govinfo.gov/content/pkg/CHRG- ... the percent increase would be 830%. And, for de novo classification requests, it would be a 6,091% increase. Even if FDA were to ... FDA-2023-N-2177-0121 20 https://aspr.hhs.gov/AboutASPR/WorkingwithASPR/BoardsandCommittees ... SPOT/Dx pilot laboratories were 96.8% (716 of 740) and 81.1%

   https://www.amp.org/AMP/assets/File/advocacy/AMP_LDT_Proposed_Rule_Comments_FINA...
8. 18.
   AMP/assets/File/education/MIMP/Bone_Soft_Tissue_2.pdf?pass=15

   Fusion FISH, NGS ~50%; POU5F1 and PBX1 are most common ... FGFR1 Fusion FISH, NGS 50-60%; FN1::FGF1 in rare cases NTRK- ... ATF1 Fusion FISH, NGS 70-90%; EWSR1::CREB1 in a subset Extraskeletal ... EWSR1::FLI1 Fusions FISH, NGS ~ 85%; EWSR1::ERG in ~ 10%, other variant fusions reported Sarcoma with ... CIC::DUX4 Fusion FISH, NGS 95%; CIC may fuse with FOXO4, LEUTX

   https://www.amp.org/AMP/assets/File/education/MIMP/Bone_Soft_Tissue_2.pdf?pass=1...
9. 19.
   PowerPoint Presentation

   B-cell lymphoma – original clonality analysis:clone 1 (69%)clone 2 (17%) clone 1 (69%)clone 2 (17%)clone 1 (69%)clone 2 (17%)Specimen #1:B-cell ... clonality analysis: clone 1 (69%)Specimen #1:B-cell lymphoma ... negative”, but with 99% confidence at 10E-5Specimen ... enough reads for a % confidence at 10E-6 ... clonality detection to MRD12.% confidence level of MRD

   https://www.amp.org/AMP/assets/File/education/ocw/Invivoscribe_May2025_slidedeck...
10. 20.
    AMP/assets/File/advocacy/AMP_Economics_of_Testing_During_Public_Health_Emergency...

    General laboratory reagents (e.g., buffers) 25% Commercially-available testing kits 61% Reagents for LDPs (e.g., RNA extraction kits, buffers) 17% Reagents required for commercially-available ... not included in kits) 25% Specimen collection materials 45% Technologists with appropriate training 49 ... 2020. Accessed March 12, 2022. https://www.congress.gov/116/plaws

    https://www.amp.org/AMP/assets/File/advocacy/AMP_Economics_of_Testing_During_Pub...